Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Anatomy and Physiology›Th17 Cells
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Th17 Cells

Anatomy and Physiology · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A subset of helper-effector T-lymphocytes which synthesize and secrete interleukins il-17; il-17f; and il-22.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (951 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A subset of helper-effector T-lymphocytes which synthesize and secrete interleukins il-17; il-17f; and il-22. These cytokines are involved in host defenses and tissue inflammation in autoimmune diseases.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: T Helper 17 Cell; T Helper 17 Cells; Type 17 Helper T Cells; TH-17 Cells; Cells, TH-17; Cell, TH-17; TH 17 Cells; TH-17 Cell.

Where it fits in the MeSH classification

Broader topics
T-Lymphocytes, Helper-Inducer

Related concepts

  • Interleukins Il-17
  • Il-17F
  • Il-22

Research landscape

PubMed indexes 12,214 records tagged with the MeSH heading “Th17 Cells” (counts retrieved 2026-10-31). 4,504 of them (36.9%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 7,826 records.

Reviews account for 1,556 records (12.7%) and meta-analyses for 25. Randomized controlled trials number 100 (0.8%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 0 records; 2000-2009: 14 records; 2010-2019: 7,826 records; 2020 onward: 4,504 records0through 1999142000-20097,8262010-20194,5042020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19990
2000-200914
2010-20197,826
2020 onward4,504
Share of records by publication typeReviews: 12.7 percent; Meta-analyses: 0.2 percent; Randomized controlled trials: 0.8 percentReviews12.7% (1,556)Meta-analyses0.2% (25)Randomized controlled trials0.8% (100)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 12,214 PubMed records
TypeRecordsShare
Reviews1,55612.7%
Meta-analyses250.2%
Randomized controlled trials1000.8%

Method: PubMed query "Th17 Cells"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in anatomy and physiology

Anatomy describes how body structures are built and physiology describes how they normally work, so most findings here are descriptive or mechanistic rather than evidence about treatment. Much of what is known comes from dissection, imaging, tissue studies and experiments in animals, and measurements in healthy volunteers can differ from those in people with disease or at different ages. Normal ranges vary between individuals and populations. Check whether a result was measured in people or in another species, the age and health of the participants, and the method used.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Microbiota-derived IPA alleviates intestinal mucosal inflammation through upregulating Th1/Th17 cell apoptosis in inflammatory bowel disease
Gao H, Sun M, Li A, Gu Q, Kang D, Feng Z, et al.
2025Research article
Design not recorded in structured metadata
90cc by
PMID 39956891 · DOI · PMC11834480
Clostridium sporogenes-derived metabolites protect mice against colonic inflammation
Krause FF, Mangold KI, Ruppert AL, Leister H, Hellhund-Zingel A, Lopez Krol A, et al.
2024Research article
Design not recorded in structured metadata
59cc by
PMID 39397690 · DOI · PMC11485882
Androgen signaling restricts glutaminolysis to drive sex-specific Th17 metabolism in allergic airway inflammation
Chowdhury NU, Cephus JY, Henriquez Pilier E, Wolf MM, Madden MZ, Kuehnle SN, et al.
2024Research article
Design not recorded in structured metadata
40cc by
PMID 39404231 · DOI · PMC11601904
Microbiota-induced T cell plasticity enables immune-mediated tumour control
Najar TA, Hao Y, Hao Y, Romero-Meza G, Dolynuk A, Almo E, et al.
2026Research article
Design not recorded in structured metadata
18cc by
PMID 41535459 · DOI · PMC12960244

Microbiota-derived IPA alleviates intestinal mucosal inflammation through upregulating Th1/Th17 cell apoptosis in inflammatory bowel disease [1]

Research article Gao H, Sun M, Li A, Gu Q, Kang D, Feng Z, et al. · · 2025 · cited 90 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The gut microbiota-derived metabolite indole-3-propionic acid (IPA) plays an important role in maintaining intestinal mucosal homeostasis, while the molecular mechanisms underlying IPA regulation on mucosal CD4+ T cell functions in inflammatory bowel disease (IBD) remain elusive.
Closing excerpt
Therefore, these findings identify a previously unrecognized pathway by which IPA modulates intestinal inflammation and provide a promising avenue for the treatment of IBD.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (254 words)

The gut microbiota-derived metabolite indole-3-propionic acid (IPA) plays an important role in maintaining intestinal mucosal homeostasis, while the molecular mechanisms underlying IPA regulation on mucosal CD4+ T cell functions in inflammatory bowel disease (IBD) remain elusive. Here we investigated the roles of IPA in modulating mucosal CD4+ T cells and its therapeutic potential in treatment of human IBD. Leveraging metabolomics and microbial community analyses, we observed that the levels of IPA-producing microbiota (e.g. Peptostreptococcus, Clostridium, and Fournierella) and IPA were decreased, while the IPA-consuming microbiota (e.g. Parabacteroides, Erysipelatoclostridium, and Lachnoclostridium) were increased in the feces of IBD patients than those in healthy donors. Dextran sulfate sodium (DSS)-induced acute colitis and CD45RBhighCD4+ T cell transfer-induced chronic colitis models were then established in mice and treated orally with IPA to study its role in intestinal mucosal inflammation in vivo. We found that oral administration of IPA attenuated mucosal inflammation in both acute and chronic colitis models in mice, as characterized by increased body weight, and reduced levels of pro-inflammatory cytokines (e.g. TNF-α, IFN-γ, and IL-17A) and histological scores in the colon. We further utilized RNA sequencing, molecular docking simulations, and surface plasmon resonance analyses and identified that IPA exerts its biological effects by interacting with heat shock protein 70 (HSP70), leading to inducing Th1/Th17 cell apoptosis. Consistently, ectopic expression of HSP70 in CD4+ T cells conferred resistance to IPA-induced Th1/Th17 cell apoptosis. Therefore, these findings identify a previously unrecognized pathway by which IPA modulates intestinal inflammation and provide a promising avenue for the treatment of IBD.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39956891 · DOI · PMC11834480

Clostridium sporogenes-derived metabolites protect mice against colonic inflammation [2]

Research article Krause FF, Mangold KI, Ruppert AL, Leister H, Hellhund-Zingel A, Lopez Krol A, et al. · · 2024 · cited 59 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Gut microbiota-derived metabolites play a pivotal role in the maintenance of intestinal immune homeostasis.
Closing excerpt
sporogenes as a therapeutically relevant probiotic bacterium that might be employed in patients with inflammatory bowel disease (IBD).
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (197 words)

Gut microbiota-derived metabolites play a pivotal role in the maintenance of intestinal immune homeostasis. Here, we demonstrate that the human commensal Clostridium sporogenes possesses a specific metabolic fingerprint, consisting predominantly of the tryptophan catabolite indole-3-propionic acid (IPA), the branched-chain acids (BCFAs) isobutyrate and isovalerate and the short-chain fatty acids (SCFAs) acetate and propionate. Mono-colonization of germ-free mice with C. sporogenes (CS mice) affected colonic mucosal immune cell phenotypes, including up-regulation of Il22 gene expression, and increased abundance of transcriptionally active colonic tuft cells and Foxp3+ regulatory T cells (Tregs). In DSS-induced colitis, conventional mice suffered severe inflammation accompanied by loss of colonic crypts. These symptoms were absent in CS mice. In conventional, but not CS mice, bulk RNAseq analysis of the colon revealed an increase in inflammatory and Th17-related gene signatures. C. sporogenes-derived IPA reduced IL-17A protein expression by suppressing mTOR activity and by altering ribosome-related pathways in Th17 cells. Additionally, BCFAs and SCFAs generated by C. sporogenes enhanced the activity of Tregs and increased the production of IL-22, which led to protection from colitis. Collectively, we identified C. sporogenes as a therapeutically relevant probiotic bacterium that might be employed in patients with inflammatory bowel disease (IBD).

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39397690 · DOI · PMC11485882

Androgen signaling restricts glutaminolysis to drive sex-specific Th17 metabolism in allergic airway inflammation [3]

Research article Chowdhury NU, Cephus JY, Henriquez Pilier E, Wolf MM, Madden MZ, Kuehnle SN, et al. · · 2024 · cited 40 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Female individuals have an increased prevalence of many Th17 cell-mediated diseases, including asthma.
Closing excerpt
AR signaling thus attenuates glutaminolysis, demonstrating sex-specific metabolic regulation of Th17 cells with implications for Th17 or glutaminolysis targeted therapeutics.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (152 words)

Female individuals have an increased prevalence of many Th17 cell-mediated diseases, including asthma. Androgen signaling decreases Th17 cell-mediated airway inflammation, and Th17 cells rely on glutaminolysis. However, it remains unclear whether androgen receptor (AR) signaling modifies glutamine metabolism to suppress Th17 cell-mediated airway inflammation. We show that Th17 cells from male humans and mice had decreased glutaminolysis compared with female individuals, and that AR signaling attenuated Th17 cell mitochondrial respiration and glutaminolysis in mice. Using allergen-induced airway inflammation mouse models, we determined that females had a selective reliance upon glutaminolysis for Th17-mediated airway inflammation, and that AR signaling attenuated glutamine uptake in CD4+ T cells by reducing expression of glutamine transporters. In patients with asthma, circulating Th17 cells from men had minimal reliance upon glutamine uptake compared to Th17 cells from women. AR signaling thus attenuates glutaminolysis, demonstrating sex-specific metabolic regulation of Th17 cells with implications for Th17 or glutaminolysis targeted therapeutics.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39404231 · DOI · PMC11601904

Microbiota-induced T cell plasticity enables immune-mediated tumour control [4]

Research article Najar TA, Hao Y, Hao Y, Romero-Meza G, Dolynuk A, Almo E, et al. · · 2026 · cited 18 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Therapies that harness the immune system to target and eliminate tumour cells have revolutionized cancer care.
Closing excerpt
Our data, as a proof of principle, define a cellular pathway by which a single, defined intestinal commensal imprints T cell plasticity that potentiates PD-1 blockade, and indicate targeted modulation of the microbiota as a strategy to broaden ICB efficacy.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (348 words)

Therapies that harness the immune system to target and eliminate tumour cells have revolutionized cancer care. Immune checkpoint blockade (ICB), which boosts the anti-tumour immune response by inhibiting negative regulators of T cell activation1-3, is remarkably successful in a subset of cancer patients. Yet a significant proportion do not respond to treatment, emphasizing the need to understand factors influencing the therapeutic efficacy of ICB4-9. The gut microbiota, consisting of trillions of microorganisms residing in the gastrointestinal tract, has emerged as a critical determinant of immune function and response to cancer immunotherapy, with several studies demonstrating association of microbiota composition with clinical response10-16. However, a mechanistic understanding of how gut commensal bacteria influence the efficacy of ICB remains elusive. Here we use a gut commensal microorganism, segmented filamentous bacteria (SFB), which induces an antigen-specific T helper 17 (TH17) cell effector program in the small intestine lamina propria (SILP)17, to investigate how colonization with this microbe affects the efficacy of ICB in restraining distal growth of tumours sharing antigen with SFB. We find that anti-programmed cell death protein 1 (PD-1) treatment effectively inhibits the growth of implanted SFB antigen-expressing melanoma only if mice are colonized with SFB. Through T cell receptor (TCR) clonal lineage tracing, fate mapping and peptide-major histocompatability complex (MHC) tetramer staining, we identify tumour-associated SFB-specific T helper 1 (TH1)-like cells derived from the homeostatic TH17 cells induced by SFB colonization in the SILP. These gut-educated ex-TH17 cells produce high levels of the pro-inflammatory cytokines interferon (IFN)-γ and tumour necrosis factor (TNF) within the tumour microenvironment (TME), enhancing antigen presentation and promoting recruitment, expansion and effector functions of CD8+ tumour-infiltrating cytotoxic lymphocytes and thereby enabling anti-PD-1-mediated tumour control. Conditional ablation of SFB-induced IL-17A+CD4+ T cells, precursors of tumour-associated TH1-like cells, abolishes anti-PD-1-mediated tumour control and markedly impairs tumour-specific CD8+ T cell recruitment and effector function within the TME. Our data, as a proof of principle, define a cellular pathway by which a single, defined intestinal commensal imprints T cell plasticity that potentiates PD-1 blockade, and indicate targeted modulation of the microbiota as a strategy to broaden ICB efficacy.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41535459 · DOI · PMC12960244

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Microbial genes and pathways in inflammatory bowel disease [5]
    Schirmer M, Garner A, Vlamakis H, Xavier RJ · Nat Rev Microbiol · 2019 · cited 746 times (Europe PMC)
  • Research article The Balance of Th17 versus Treg Cells in Autoimmunity [6]
    Lee GR · Int J Mol Sci · 2018 · cited 672 times (Europe PMC)
  • Research article The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies [7]
    Brunner PM, Guttman-Yassky E, Leung DY · J Allergy Clin Immunol · 2017 · cited 513 times (Europe PMC)
  • Research article When worlds collide: Th17 and Treg cells in cancer and autoimmunity [8]
    Knochelmann HM, Dwyer CJ, Bailey SR, Amaya SM, Elston DM, Mazza-McCrann JM, et al. · Cell Mol Immunol · 2018 · cited 457 times (Europe PMC)
  • Research article The pathogenicity of Th17 cells in autoimmune diseases [9]
    Yasuda K, Takeuchi Y, Hirota K · Semin Immunopathol · 2019 · cited 443 times (Europe PMC)
  • Research article The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond [10]
    Brembilla NC, Senra L, Boehncke WH · Front Immunol · 2018 · cited 400 times (Europe PMC)

References

  1. Gao H, Sun M, Li A, Gu Q, Kang D, Feng Z, et al.. Microbiota-derived IPA alleviates intestinal mucosal inflammation through upregulating Th1/Th17 cell apoptosis in inflammatory bowel disease. . 2025. PMID 39956891 · DOI · PMC11834480
  2. Krause FF, Mangold KI, Ruppert AL, Leister H, Hellhund-Zingel A, Lopez Krol A, et al.. Clostridium sporogenes-derived metabolites protect mice against colonic inflammation. . 2024. PMID 39397690 · DOI · PMC11485882
  3. Chowdhury NU, Cephus JY, Henriquez Pilier E, Wolf MM, Madden MZ, Kuehnle SN, et al.. Androgen signaling restricts glutaminolysis to drive sex-specific Th17 metabolism in allergic airway inflammation. . 2024. PMID 39404231 · DOI · PMC11601904
  4. Najar TA, Hao Y, Hao Y, Romero-Meza G, Dolynuk A, Almo E, et al.. Microbiota-induced T cell plasticity enables immune-mediated tumour control. . 2026. PMID 41535459 · DOI · PMC12960244
  5. Schirmer M, Garner A, Vlamakis H, Xavier RJ. Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol. 2019. PMID 31249397 · DOI · PMC6759048
  6. Lee GR. The Balance of Th17 versus Treg Cells in Autoimmunity. Int J Mol Sci. 2018. PMID 29510522 · DOI · PMC5877591
  7. Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017. PMID 28390479 · DOI · PMC5405702
  8. Knochelmann HM, Dwyer CJ, Bailey SR, Amaya SM, Elston DM, Mazza-McCrann JM, et al.. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018. PMID 29563615 · DOI · PMC6068176
  9. Yasuda K, Takeuchi Y, Hirota K. The pathogenicity of Th17 cells in autoimmune diseases. Semin Immunopathol. 2019. PMID 30891627 · DOI
  10. Brembilla NC, Senra L, Boehncke WH. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front Immunol. 2018. PMID 30127781 · DOI · PMC6088173

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Th2 CellsAnatomy and Physiology
  • Th1 CellsAnatomy and Physiology
  • T-LymphocytesAnatomy and Physiology
  • B-LymphocytesAnatomy and Physiology
  • Plasma CellsAnatomy and Physiology
  • LymphocytesAnatomy and Physiology

All 542 articles in Anatomy and Physiology →

At a glance

12,214
PubMed records on this heading
37%
published since 2020
1,556
review articles
100
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Th2 CellsAnatomy and Physiology
  • Th1 CellsAnatomy and Physiology
  • T-LymphocytesAnatomy and Physiology
  • B-LymphocytesAnatomy and Physiology
  • Plasma CellsAnatomy and Physiology

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support